NeuroSense Therapeutics Ltd. Amounts Incurred Deferred Acquisition Costs Arising From Insurance Contracts
NeuroSense Therapeutics Ltd. (NRSN) reported Amounts Incurred Deferred Acquisition Costs Arising From Insurance Contracts of $70.00 thousand for the 12-month period ending 2022-12-31, per its 20-F filed 2023-03-22.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:AmountsIncurredDeferredAcquisitionCostsArisingFromInsuranceContracts · last filed 2023-03-22
| Period end | Amounts Incurred Deferred Acquisition Costs Arising From Insurance Contracts 12 month |
|---|---|
| 2022-12-31 | $70.00K 20-F · filed 2023-03-22 |
| 2021-12-31 | $17.00K 20-F · filed 2023-03-22 |
| 2020-12-31 | $9.00K 20-F · filed 2022-04-14 |